In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38085269.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3087.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemo-immunotherapy is the current standard of care for extensive-stage small cell lung cancer, but predictive biomarkers are lacking. In a recent article, the authors report the predictive role of programmed death ligand-1 expression and tissue tumor mutational burden on durvalumab ± tremelimumab + platinum-etoposide efficacy. See related article by Paz-Ares et al., p. 824.
Medical subject headings
- Small Cell Lung Carcinoma
- Lung Neoplasms